The FDA could soon approve the first drug developed explicitly for a tissue-agnostic cancer indication, but biological complexity may limit this approach.
This is a preview of subscription content, log in via an institution to check access.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Garber, K. Tissue-agnostic cancer drug pipeline grows, despite doubts. Nat Rev Drug Discov 17, 227–229 (2018). https://doi.org/10.1038/nrd.2018.6
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.6
- Springer Nature Limited
This article is cited by
-
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases
Cancer Cell International (2022)
-
The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology
Virchows Archiv (2020)
-
Tumor-Agnostic Treatment for Cancer: When How is Better than Where
Clinical Drug Investigation (2020)
-
FDA approves landmark tissue-agnostic cancer drug
Nature Reviews Drug Discovery (2019)
-
Public biotech in 2017—the numbers
Nature Biotechnology (2018)